814 related articles for article (PubMed ID: 32212262)
21. Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis.
Sasaki T; Kanata R; Yamada I; Matsuyama M; Ozaka M; Sasahira N
In Vivo; 2019; 33(1):271-276. PubMed ID: 30587635
[TBL] [Abstract][Full Text] [Related]
22. Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy.
McAndrew EN; Zhang H; Lambert P; Rittberg R; Dawe DE; Kim CA
Am J Clin Oncol; 2022 Feb; 45(2):55-60. PubMed ID: 35073280
[TBL] [Abstract][Full Text] [Related]
23. A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer.
Cui H; Guan J; Deng G; Yuan J; Lou C; Zhang W; Zhou A; Zhang Y; Zhou J; Dai G
Med Sci Monit; 2020 Oct; 26():e927654. PubMed ID: 33100319
[TBL] [Abstract][Full Text] [Related]
24. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Wattenberg MM; Asch D; Yu S; O'Dwyer PJ; Domchek SM; Nathanson KL; Rosen MA; Beatty GL; Siegelman ES; Reiss KA
Br J Cancer; 2020 Feb; 122(3):333-339. PubMed ID: 31787751
[TBL] [Abstract][Full Text] [Related]
25. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
[TBL] [Abstract][Full Text] [Related]
26. Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
Abrams TA; Meyer G; Meyerhardt JA; Wolpin BM; Schrag D; Fuchs CS
Oncologist; 2017 Aug; 22(8):925-933. PubMed ID: 28476943
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Cui J; Zhang X; Qu S; Wang L
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):691-697. PubMed ID: 32976031
[TBL] [Abstract][Full Text] [Related]
28. Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
Smyth EN; Bapat B; Ball DE; André T; Kaye JA
Clin Ther; 2015 Jun; 37(6):1301-16. PubMed ID: 25907619
[TBL] [Abstract][Full Text] [Related]
29. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Santucci J; Tacey M; Thomson B; Michael M; Wong R; Shapiro J; Jennens R; Clarke K; Pattison S; Burge M; Zielinski R; Nikfarjam M; Ananda S; Lipton L; Gibbs P; Lee B
Eur J Cancer; 2022 Oct; 174():102-112. PubMed ID: 35988408
[TBL] [Abstract][Full Text] [Related]
30. First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population.
Hatashima A; Arango MJ; Reardon J; Freeman T; Williams T; McLaughlin EM; Abushahin L
Future Oncol; 2022 Jun; 18(20):2521-2532. PubMed ID: 35579260
[TBL] [Abstract][Full Text] [Related]
31. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.
Kang J; Hwang I; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Hong SM; Shin SH; Hwang DW; Song KB; Lee JH; Kim SC; Ryoo BY
Invest New Drugs; 2018 Aug; 36(4):732-741. PubMed ID: 29616439
[TBL] [Abstract][Full Text] [Related]
32. Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
Surinach A; Phung T; Abdul-Rahim O; Khushman M
Curr Oncol; 2020 Apr; 27(2):e222-e225. PubMed ID: 32489272
[TBL] [Abstract][Full Text] [Related]
33. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
34. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
Shibuki T; Mizuta T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Taguchi H; Honda T; Mitsugi K; Nio K; Ide Y; Ureshino N; Shirakawa T; Otsuka T
BMC Cancer; 2022 Jan; 22(1):19. PubMed ID: 34980029
[TBL] [Abstract][Full Text] [Related]
35. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
Franco F; Camara JC; Martín-Valadés JI; López-Alfonso A; Marrupe D; Gutiérrez-Abad D; Martínez-Amores B; León A; Juez I; Pérez M; Royuela A; Ruiz-Casado A
Clin Transl Oncol; 2021 Apr; 23(4):812-819. PubMed ID: 32857340
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
Zhou J; Zhao R; Wen F; Zhang P; Wu Y; Tang R; Chen H; Zhang J; Li Q
Tumori; 2016 Jun; 2016(3):294-300. PubMed ID: 27056335
[TBL] [Abstract][Full Text] [Related]
38. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
[TBL] [Abstract][Full Text] [Related]
39. FOLFIRINOX
Begg SKS; Birnbaum DJ; Clark JW; Mino-Kenudson M; Wellner UF; Schilling O; Lillemoe KD; Warshaw AL; Castillo CF; Liss AS
Anticancer Res; 2020 Jul; 40(7):3659-3667. PubMed ID: 32620605
[TBL] [Abstract][Full Text] [Related]
40. The economic burden of metastatic pancreatic cancer.
Malangone-Monaco E; Doleh Y; Cole A; Noxon V; Antico G; Pishvaian MJ
Pancreatology; 2020 Oct; 20(7):1434-1441. PubMed ID: 32967794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
